---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-23-014163"
form_type: "8-K"
ticker: "ZOMDF"
cik: "0001684144"
company_name: "Zomedica Corp."
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T05:15:49.446984+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Zomedica Q3 revenue up 31% to record $6.3M; net loss narrows to $0.3M; NYSE listing deficiency

## Summary
- Revenue of $6.3M, up 31% YoY; gross margin 69%, up from 67% sequential.
- Net loss narrowed to $0.3M ($0.001/share) from $5.8M ($0.005/share) a year ago.
- Non-GAAP EBITDA loss $0.3M vs $3.0M loss; adjusted non-GAAP EBITDA profit $0.3M.
- Liquidity $118M; completed acquisitions of SMP (VetGuardian) and Qorvo Biotechnologies.
- NYSE American notified of low share price deficiency; 30-day avg <$0.20; company plans cure.

## SEC filing metadata
- accession: 0001654954-23-014163
- form_type: 8-K
- ticker: ZOMDF
- cik: 0001684144
- company_name: Zomedica Corp.
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1684144/000165495423014163/0001654954-23-014163-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1684144/000165495423014163/zom_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-23-014163
- JSON: https://secwatch.observer/filing/0001654954-23-014163.json
- Plain text: https://secwatch.observer/filing/0001654954-23-014163.txt

## Key facts
- Earnings Releases
  Zomedica Corp. reported the quarter ended September 30, 2023 results: revenue $6.3 million.
  - Period: the quarter ended September 30, 2023
  - Revenue: $6.3 million
  - Result: reported results
  source text: EX-99.1 (PRESS RELEASE) --- EX-99.1 2 zom_ex991.htm PRESS RELEASE zom_ex991.htm EXHIBIT 99.1 Zomedica Announces Record Third Quarter 2023 Financial Results: Revenue up 31% to $6.3 Million; 69% Gross Margin, and $118 Million in Liquidity, while Making Strategic Acquisitions of Structured Monitoring Products and Qorvo Biotechnologies ANN ARBOR, MI / ACCESSWIRE /
  evidence_url: https://www.sec.gov/Archives/edgar/data/1684144/000165495423014163/0001654954-23-014163-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.